Skip to main content

Table 2 Changes in CXCL13 levels with different therapies in RA

From: A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis

Study Population Study Substrate CXCL13 levels with treatment
Moura et al. (2017) [15] N = 33. ERA, EstRA
Anti-TNF, anti-IL6R
Cohort Serum by ELISA No change with: ADA, GOL, ETN or TCZ
Rinaldi et al.* (2017) [33] N = 34. EstRA Anti-IL6R RCT Serum, method not published Reduction with anti-IL-6 (TCZ, vobarilizumab)
Han et al. (2016) [16] N = 29. EstRA Anti-TNF Cohort Serum by ELISA Reduction with TNF (ADA/ETN) in TNF responders
B/L high level associated greater response
Bugatti et al.* (2016) [34] N = 205. ERA
csDMARD
Cohort Serum, method not published B/L high levels predict failure of remission
Kumagai et al.* (2016) [17] N = 146. EstRA
Anti-TNF
Cohort Serum by ELISA Reduction with ADA in ADA responder.
Not seen with IFX
Loza et al.* (2016) [18] N = 916. ERA
Anti-IL6
Cohort Serum by ELISA, MSD, Luminex No change with sirukumab
Bugatti et al.* (2016) [19] N = 213. EstRA
csDMARD
Cohort Both, method not published B/L high levels predict failure of remission
Greisen et al. (2014) [23] N = 114. ERA
csDMARD, Anti-TNF
Cohort Serum by ELISA Correlate with treatment response.
B/L high level predict ADA treatment remission
Bugatti et al.* (2014) [24] N = 205
csDMARD
Cohort Serum by ELISA No change with treatment
de Jong et al. (2014) [35] N = 18
Anti-CD20
Cohort Serum by Luminex Reduction with rituximab irrespective of responder status
El-Sherbiny et al.* (2013) [36] N = 23
Anti-CD20
Cohort Synovial by mRNA qPCR Reduction with rituximab in rituximab responders
Taylor et al. (2017) * [37] N = 65 EstRA
JAKi
RCT Serum, method not published Reduction with filgotinib. No change with placebo
Gabay et al. (2016) [38] N = 356 EstRA
Anti-IL6R
RCT Serum by ELISA Reduction with sarilumab (p < 0.01) from 2 weeks
Boyle et al. (2015) [39] N = 29 EstRA
JAKi
RCT Serum by ELISA Reduction with tofacitinib. No change with placebo
Dennis et al. (2014) [40] N = 198. EstRA
Anti-TNF, anti-IL6R
RCT Serum by ECLA Low B/L levels associate greater response to ADA
High B/L levels associated greater response to TCZ
Kennedy et al. (2014) [41] N = 214. EstRa
Anti-TNF, antiLTα
RCT Serum by ELISA & MSD Reduction with ADA and pateclizumab.
Herman et al. (2013) [42] N = 325. EstRa
Anti-TNF, anti-IL6
RCT Serum, method not published Reduction with ADA, correlates with ADA response Reduction with TCZ, B/L high levels predict response
Emu et al. * (2012) [43] N = 65
antiLTα
RCT Serum by ELISA Reduction with pateclizumab
Rosengren et al. (2011) [44] N = 24, Anti-CD20 Cohort Both by ELISA, mRNA qPCR Reduction with rituximab at 2 months, which was maintained at 6 months
  1. * Abstract only. ERA Early RA, EstRA Established RA, HC Healthy control, csDMARDs Conventional synthetic disease-modifying anti-rheumatic drugs, bDMARDs Biologic disease-modifying anti-rheumatic drugs, TNFi Tumour Necrosis Factor inhibitor drug, ADA Adalimumab, ETN Etanercept, antiIL-6R Anti-interleukin 6 receptor. DAS28 Disease activity score for 28 joint count, SJC Swollen joint count, TJC Tender joint count, PGA Patient global assessment, RF Rheumatoid factor, ACPA Anti–citrullinated peptide antibodies